05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Antibiotic tablets; antibiotics; antibiotics for human use; antiseptics; bacterial poisons; cardiovascular pharmaceutical preparations; chinese traditional medicinal herbs for controlling blood pressure; collyrium; dietetic substances consisting of vitamins, minerals, amino acids and trace elements; disinfectants for sterilization; eyepatches for medical purposes; herbal supplements for the treatment of cardiovascular diseases; medical dressings; natural medicines for improving heart function; pharmaceutical preparations for maintaining normal blood pressure and heart function; pharmaceutical preparations for the treatment of blood disorders; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; slimming pills; surgical dressings; vitamin preparations
2.
THYROID HORMONE β RECEPTOR AGONIST, CRYSTAL FORM, PREPARATION METHOD AND USE
The present invention belongs to the field of medicines. Disclosed in the present invention are a thyroid hormone β receptor agonist, a crystal form, a preparation method and the use. The compound is a compound having a structural formula as represented by formula (I) or a pharmaceutically acceptable salt thereof. The X-ray powder diffraction pattern of a crystal form A of the compound of formula (I) comprises characteristic peaks at 6.10±0.20°, 12.08±0.20° and 16.49±0.20° 2θ, as determined by means of using Cu-Ka radiation. The present invention develops a new 2-pyridone derivative. The compound has high agonistic activity and selectivity for the thyroid hormone β receptor, and can be used for treating metabolic diseases, particularly for treating diseases related to thyroid hormone receptor. The present invention also studies a series of crystal forms of the compound. The crystal form A compound has the advantages of good stability, low hygroscopicity, and small heat influence.
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
The present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. Activity experiment results show that the 2-pyridone derivative provided in the present invention has higher activity and selectivity, and can be used to treat thyroid hormone receptor-related diseases.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invention has a selective agonistic effect on THRβ, and the activity, selectivity, and metabolic stability thereof have significant advantages over disclosed compounds, and can function as a therapeutic and/or preventive drug for thyroid hormone receptor related diseases, comprising, but not limited to, obesity, diabetes, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, liver steatosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, familial hypercholesterolemia, dyslipidemia, atherosclerosis, hypothyroidism, and thyroid cancer.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
5.
SALT FORM AND CRYSTAL FORM OF MUTANT IDH1 INHIBITOR AND PREPARATION METHOD THEREFOR
A salt form and crystal form of a mutant IDHI inhibitor and a preparation method therefor.
A salt form and crystal form of a mutant IDHI inhibitor and a preparation method therefor.
The present invention provides a benzopyrimidine tricyclic derivative, a preparation method therefor, and an application thereof. The benzopyrimidine tricyclic derivative provided in the present invention has the structure of formula (I), is capable of inhibiting the interaction of a SOS1 catalytic site and Ras family protein, displays excellent inhibition effects with respect to SOS1 inhibitors, and can be used for treating and/or preventing oncological diseases.
Disclosed in the present invention are a salt form and a crystal form of a 1,2,4-triazine-3,5-dione (Formula I) compound, a preparation method therefor, and the use thereof in the treatment and/or the preparation of a drug. The use is to treat diseases related to thyroid hormone receptors.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61P 5/16 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
8.
2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
The present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. Activity experiment results show that the 2-pyridone derivative provided in the present invention has higher activity and selectivity, and can be used to treat thyroid hormone receptor-related diseases.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
9.
2-PYRIDONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
The present invention provides a 2-pyridone derivative having a structure represented by formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. Activity experiment results show that the 2-pyridone derivative provided in the present invention has higher activity and selectivity, and can be used to treat thyroid hormone receptor-related diseases.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
The present invention provides a 2,6-disubstituted 1,2,4-triazine-3,5-dione compound having a structure represented by Formula I, or a pharmaceutically acceptable salt thereof. The above triazone derivative has a novel structure and exhibits an excellent THRβ agonistic effect, and can therefore play a role as a drug for the treatment and/or prophylaxis of a thyroid hormone receptor-related disease.
C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
11.
Benzimidazole derivatives and use thereof as IDH1 inhibitors
The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.
The present disclosure belongs to the biopharmaceutical field, and discloses uses of Trezastilbenoside in manufacture of a product for treating and/or preventing a disease of respiratory system, and particularly uses of Trezastilbenoside in manufacture of a product for treating and/or preventing a disease of respiratory system with symptoms of cough and/or expectoration and/or asthma. As indicated by the test results of the present disclosure, Trezastilbenoside has significant efficacy of relieving cough, eliminating phlegm, relieving asthma and anti-inflammation, and has a potential therapeutic effect on respiratory system diseases, thus possessing broad prospects in clinical application.
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invention has a selective agonistic effect on THR?, and the activity, selectivity, and metabolic stability thereof have significant advantages over disclosed compounds, and can function as a therapeutic and/or preventive drug for thyroid hormone receptor related diseases, comprising, but not limited to, obesity, diabetes, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, liver steatosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, familial hypercholesterolemia, dyslipidemia, atherosclerosis, hypothyroidism, and thyroid cancer.
A61P 5/16 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
16.
1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invention has a selective agonistic effect on THRβ, and the activity, selectivity, and metabolic stability thereof have significant advantages over disclosed compounds, and can function as a therapeutic and/or preventive drug for thyroid hormone receptor related diseases, comprising, but not limited to, obesity, diabetes, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, liver steatosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, familial hypercholesterolemia, dyslipidemia, atherosclerosis, hypothyroidism, and thyroid cancer.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 5/16 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
17.
BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS IDH1 INHIBITORS
The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.
rheum officinale; extracting the medicinal material with a herbal flash extractor for one to four times, 5-20 minutes each time; filtering and combining filtrate and concentrating the filtrate to dryness; the proportion of the medicinal material to a solvent being 1 g: 10 ml-1 g:15 ml.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary food supplements; dietary and nutritional supplements; dietetic foods adapted for medical purposes; food supplements; ginseng for medicinal use; health food supplements; herbal extracts for medical purposes; herbal supplements; herbs for medicinal purposes; liquid herbal supplements; medicinal herbs; mineral food supplements; natural herbal supplements; nutritional supplements; protein dietary supplements; vitamins
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicines for human purposes; pharmaceutical preparations in
the form of injection; pharmaceutical preparations in the
form of tablet; raw material medicine; prepared Chinese
medicine; biochemical medicines; antibiotics; slimming
pills; radioactive drugs; gases for medical purposes;
disinfectants; contact lens cleaning preparations; media for
bacteriological cultures; dietetic substances adapted for
medical use; depuratives; medicines for veterinary purposes;
fungicides for agricultural purposes; antisepsis paper;
Chinese medicine filled in bags.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medicines for human purposes; pharmaceutical preparations in
the form of injection; pharmaceutical preparations in the
form of tablet; raw material medicine; prepared Chinese
medicine; biochemical medicines; antibiotics; slimming
pills; radioactivity drugs; gases for medical purposes;
disinfectants; contact lens cleaning preparations; media for
bacteriological cultures; dietetic substances adapted for
medical use; depuratives; medicines for veterinary purposes;
fungicides for agricultural purposes; antisepsis paper;
Chinese medicine filled in bags. Medical apparatus and instruments; nursing appliances;
radiological apparatus for medical purposes; physiotherapy
apparatus; furniture especially made for medical purposes;
surgical implants (artificial materials); orthopedic
articles; suture materials. Hospital services; medical clinic services; therapy
services; telemedicine services; plastic surgery; health
center services; health spa services; animal grooming;
gardening; opticians' services.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
medicines for human purposes for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; pharmaceutical preparations in the form of injection for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; pharmaceutical preparations in the form of tablet for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; raw material medicine for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; prepared Chinese medicine for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; biochemical medicines for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; antibiotics for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; medicinal pills for slimming purposes; radioactive drugs for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; gases for medical purposes for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; disinfectants; contact lens cleaning preparations; media for bacteriological cultures; dietetic foods, namely, pasta and crackers adapted for medical use; depuratives; medicines for veterinary purposes for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout; fungicides for agricultural purposes; antisepsis paper; Chinese medicine filled in bags for the treatment of cardio-cerebrovascular disease, nervous system disease, anti-malaria, diabetes, Rheumatoid arthritis gout
23.
AMORPHOUS PICEATANNOL 3'-O-GLUCOSIDE AND PREPARATION METHOD THEREOF
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a new amorphous piceatannol 3'-O-glucoside, preparation method thereof, and pharmaceutical composition containing the same. The amorphous piceatannol 3'-O-glucoside has favorable performances in stability and solubility. The preparation method for the amorphous piceatannol 3'-O-glucoside in the present invention is easy to operate, and the resulting product has a high yield, and is suitable for development of a laboratory and industrial production, thus having a wide application. The amorphous piceatannol 3'-O-glucoside product prepared by the method in the present invention has a stable quality, a favorable solubility, and can be directly used to prepare medicine treating cardiovascular diseases and cerebrovascular diseases.
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61P 9/00 - Drugs for disorders of the cardiovascular system
24.
Pegylated artesunate derivative, pharmaceutical composition and use thereof
Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. CHINA (China)
Inventor
Li, Sicheng
Meng, Qingbin
Mao, Junwen
Li, Jinfeng
Xu, An
Liu, Jia
Liang, Yuanjun
Jia, Qiyan
Yan, Jiufeng
Shen, Xiaoyang
Liu, Hui
Xing, Na
Abstract
A pegylated artesunate derivative, a pharmaceutical composition and uses thereof, the pegylated artesunate derivative is represented by the general formula (I):
The pegylated artesunate derivative has activity comparable to that of artesunate, increased water solubility and stability, and an extended half-life in vivo.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
C07D 323/00 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C08G 65/332 - Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides or esters thereof
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
C08G 65/333 - Polymers modified by chemical after-treatment with organic compounds containing nitrogen
A method for extracting stilbene compounds comprises the following steps: grinding a medicinal material rich in stilbene compounds such as rheum officinale; extracting the medicinal material with a herbal blitzkrieg extractor for one to four times, 5-20 minutes each time; filtering and combining filtrate and concentrating the filtrate to dryness; the proportion of the medicinal material to a solvent being 1 g:10 ml-1 g:15 ml.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 125/00 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes
